Search results for "PLACEBO"

showing 10 items of 704 documents

Placebo and Nocebo Effects Across Symptoms: From Pain to Fatigue, Dyspnea, Nausea, and Itch

2019

Contains fulltext : 208540.pdf (Publisher’s version ) (Open Access) Placebo and nocebo effects are, respectively, the helpful and harmful treatment effects that do not arise from active treatment components. These effects have thus far been researched most often in pain. It is not yet clear to what extent these findings from pain can be generalized to other somatic symptoms. This review investigates placebo and nocebo effects in four other highly prevalent symptoms: dyspnea, fatigue, nausea, and itch. The role of learning mechanisms (verbal suggestions, conditioning) in placebo and nocebo effects on various outcomes (self-reported, behavioral, and physiological) of these different somatic s…

medicine.medical_specialtyNoceboNausealcsh:RC435-571Reviewplacebo and nocebo effectsPlacebo03 medical and health sciences0302 clinical medicinesuggestionconditioninglcsh:PsychiatryHeart ratemedicinepainitchLung functionPsychiatrybusiness.industrydyspneanausea030227 psychiatry3. Good healthNocebo EffectPsychiatry and Mental healthPhysical therapyInflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5]fatigueActive treatmentmedicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Effect of oral magnesium supplementation on physical performance in healthy elderly women involved in a weekly exercise program: A randomized control…

2014

Background: Magnesium deficiency is associated with poor physical performance, but no trials are available on how magnesium supplementation affects elderly people’s physical performance. Objective: The aim of our study was to investigate whether 12 wk of oral magnesium supplementation can improve physical performance in healthy elderly women. Design: In a parallel-group, randomized controlled trial, 139 healthy women (mean 6 SD age: 71.5 6 5.2 y) attending a mild fitness program were randomly allocated to a treatment group (300 mg Mg/d; n = 62) or a control group (no placebo or intervention; n = 77) by using a computer-generated randomization sequence, and researchers were blinded to their …

medicine.medical_specialtyNutrition and DieteticsRandomizationbusiness.industryMedicine (miscellaneous)physical activitymagnesiummedicine.diseasePlaceboReference Daily Intakelaw.inventionHypomagnesemiaolder peopleRandomized controlled trialDietary Reference IntakelawMagnesium deficiency (medicine)Hand strengthmedicinePhysical therapybusiness
researchProduct

Effects of alfa-hydroxy-isocaproic acid on body composition, DOMS and performance in athletes

2010

Abstract Background Alfa-Hydroxy-isocaproic acid (HICA) is an end product of leucine metabolism in human tissues such as muscle and connective tissue. According to the clinical and experimental studies, HICA can be considered as an anti-catabolic substance. The present study investigated the effects of HICA supplementation on body composition, delayed onset of muscle soreness (DOMS) and physical performance of athletes during a training period. Methods Fifteen healthy male soccer players (age 22.1+/-3.9 yr) volunteered for the 4-week double-blind study during an intensive training period. The subjects in the group HICA (n = 8) received 583 mg of sodium salt of HICA (corresponding 500 mg of …

medicine.medical_specialtyNutrition and DieteticsSports medicinebiologyStrength trainingAthletesbusiness.industrylcsh:TX341-641Clinical nutritionPlaceboBody weightbiology.organism_classificationEndocrinologyInternal medicineResearch articleLean body massPhysical therapymedicineComposition (visual arts)lcsh:Sports medicinelcsh:RC1200-1245businesslcsh:Nutrition. Foods and food supplyFood ScienceJournal of the International Society of Sports Nutrition
researchProduct

Mepolizumab for eosinophilic chronic obstructive pulmonary disease

2017

BACKGROUNDPatients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed against interleukin-5.METHODSWe performed two phase 3, randomized, placebo-controlled, double-blind, parallel-group trials comparing mepolizumab (100 mg in METREX, 100 or 300 mg in METREO) with placebo, given as a subcutaneous injection every 4 weeks for 52 weeks in patients with COPD who had a history of moderate or severe exacerbations while taking inhaled glucocorticoid-based triple maintenance therapy. In METREX, unselected patients in the modified intention-to-treat population with an eosinophilic phenotype were …

medicine.medical_specialtyPARALLEL-GROUPPopulationPlacebo-controlled studyPNEUMONIA RISKPlaceboPLACEBO-CONTROLLED TRIALGastroenterology03 medical and health sciencesDOUBLE-BLIND0302 clinical medicineMaintenance therapyInternal medicineEosinophilicmedicineINHALED FLUTICASONE FUROATE030212 general & internal medicineeducationCOPDeducation.field_of_studyIntention-to-treat analysisCOPD ASSESSMENT TESTSPUTUM EOSINOPHILIAbusiness.industryGeneral MedicineRANDOMIZED CONTROLLED-TRIALBLOOD EOSINOPHILSmedicine.diseaseSECONDARY ANALYSIS030228 respiratory systemImmunologybusinessMepolizumabmedicine.drug
researchProduct

Comparing medical treatments for Crohn’s disease

2013

The drugs available for inflammatory bowel disease are aminosalicylates, antibiotics, steroids, immunosuppressors and biologics. The effectiveness of these drugs has been evaluated in many randomized clinical trials, mainly versus placebo. Few studies have been conducted comparing the different drugs among themselves, owing to the methodological problems raised by comparative trials, such as sample size and blindness. This review focuses mainly on the randomized clinical trials that have compared different treatments. Of course comparisons are mainly between drugs used in a particular setting (mild, moderate and severe disease). However, on many occasions there is no homogeneity in these cl…

medicine.medical_specialtyPathologymedicine.drug_classAntibioticsAlternative medicineSevere diseasePlaceboInflammatory bowel diseaselaw.inventionBiological FactorsCrohn DiseaseRandomized controlled trialAdrenal Cortex HormoneslawInternal medicineAzathioprineIntestinal FistulaSecondary PreventionmedicineHumansBudesonideRandomized Controlled Trials as TopicCrohn's diseasebusiness.industryProbioticsHealth Policymedicine.diseaseAnti-Bacterial AgentsAminosalicylic AcidsMethotrexateSample size determinationbusinessJournal of Comparative Effectiveness Research
researchProduct

Deflazacort in Duchenne dystrophy: Study of long-term effect

1994

A randomized double-blind controlled trial of deflazacort was conducted in 28 Duchenne muscular dystrophy patients either treated with deflazacort 2.0 mg/kg alternate-day therapy or placebo. The deflazacort group showed significant improvement in climbing stairs (P < 0.01), in rising from a chair, Gower's maneuver, and walking (P < 0.0025) after 6 months of treatment. After 1 year, all the above changes remained significantly improved and the MRC index was significantly better (P < 0.05) in the treated group. After 2 years, a significant change was found in the MRC index: higher scores in walking, chair rising (P < 0.02), and grade and time of Gower's maneuver (P < 0.05) were found. The mea…

medicine.medical_specialtyPatient DropoutsTime Factorsmedicine.drug_classPhysiologyDuchenne muscular dystrophymedicine.medical_treatmentMotor ActivityPlaceboMuscular Dystrophieslaw.inventionCellular and Molecular NeuroscienceDouble-Blind MethodRandomized controlled trialPregnenedioneslawPhysiology (medical)medicineHumansChildGaitChemotherapybusiness.industryMusclesAnti-Inflammatory Agents Non-SteroidalBody Weightmedicine.diseaseSurgeryClinical trialDeflazacortAnesthesiaCorticosteroidNeurology (clinical)medicine.symptombusinessWeight gainFollow-Up Studiesmedicine.drugMuscle &amp; Nerve
researchProduct

Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (…

2016

Background: RES reduced exacerbation frequency and improved lung function and asthma control in pts with inadequately controlled asthma and elevated blood eosinophils (EOS) in two PBO-controlled, phase 3 trials (Castro et al. Lancet Resp Med 2015). Aims/objectives: To determine the efficacy of RES in asthma pts stratified by GINA Step 4 (G4) and Step 5 (G5) categories of asthma severity. Methods: Pooled data from two 52-week, PBO-controlled trials of RES (3mg/kg IV Q4W) in pts with inadequately controlled asthma and blood EOS ≥400/µL on inhaled corticosteroid (ICS) ± another controller; primary results have been reported. Current analysis includes pts stratified by G4 (medium/high-dose ICS …

medicine.medical_specialtyPediatricsExacerbationbusiness.industrymedicine.drug_classEosinophilic asthmaPlaceboRate ratiomedicine.diseaserespiratory tract diseases03 medical and health sciences0302 clinical medicine030228 respiratory systemReslizumabInternal medicineAsthma controlMedicineCorticosteroid030212 general & internal medicinebusinessmedicine.drugAsthma5.1 Airway Pharmacology and Treatment
researchProduct

Effects of Group Psychotherapy, Individual Counseling, Methylphenidate, and Placebo in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder

2015

Importance Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder with high prevalence in adulthood. There is a recognized need to assess the efficacy of psychotherapy in adult ADHD. Objective To evaluate the efficacy of cognitive behavioral group psychotherapy (GPT) compared with individual clinical management (CM) and that of methylphenidate hydrochloride compared with placebo. Design, Setting, and Participants Prospective, multicenter, randomized clinical trial of 18- to 58-year-old outpatients with ADHD from 7 German study centers. Patients were recruited between January 2007 and August 2010, treatment was finalized in August 2011, and final follow-up assessmen…

medicine.medical_specialtyPediatricsMethylphenidatemedicine.medical_treatmentMedizinmedicine.diseasePlacebo030227 psychiatry3. Good healthlaw.inventionGroup psychotherapyCognitive behavioral therapy03 medical and health sciencesPsychiatry and Mental health0302 clinical medicineRandomized controlled triallawClinical Global ImpressionmedicineAttention deficit hyperactivity disorderMethylphenidate HydrochloridePsychiatryPsychology030217 neurology & neurosurgerymedicine.drugJAMA Psychiatry
researchProduct

EPA-0666 – Long-term maintenance of efficacy of extended-release guanfacine hydrochloride (GXR) in children and adolescents with attention-deficit/hy…

2014

Introduction GXR, a selective α2A-adrenergic agonist, is a non-stimulant ADHD treatment approved in the USA for children and adolescents, and in Canada for children. Objectives To evaluate long-term maintenance of efficacy of GXR in children and adolescents with ADHD who respond to an initial open-label, short-term trial. Aims To determine if there is a higher rate of treatment failure for placebo vs GXR during the double-blind randomised-withdrawal phase (RWP) (NCT01081145). Methods Patients (6–17 years) meeting DSM-IV-TR criteria for ADHD, baseline ADHD Rating Scale-IV (ADHD-RS-IV) ≥32 and Clinical Global Impressions-Severity (CGI-S) ratings ≥4 were enrolled. Following 7-week dose optimiz…

medicine.medical_specialtyPediatricsbusiness.industryVital signsLong term maintenancemedicine.diseasePlaceboDouble blindPsychiatry and Mental healthmental disordersPhysical therapymedicineClinical endpointAttention deficit hyperactivity disorderGuanfacine HydrochlorideAdverse effectbusinessEuropean Psychiatry
researchProduct

A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic ha…

2021

BACKGROUND: Cytomegalovirus (CMV) is a complication of allogeneic haematopoietic cell transplantation (allo-HCT). ASP0113, a DNA-based vaccine, contains two plasmids encoding human CMV glycoprotein B and phosphoprotein 65 (pp65). We assessed ASP0113 in CMV-seropositive allo-HCT recipients. METHODS: In this phase 3, randomised, placebo-controlled study, CMV-seropositive allo-HCT recipients were randomly assigned (1:1) via interactive response technology to receive five injections of 1 mL of 5 mg/mL ASP0113 or placebo. The pharmacist and designated staff were unblinded. Masked syringes maintained the blind for patients and study personnel. Efficacy and safety analyses included patients who re…

medicine.medical_specialtyPhases of clinical research[SDV.CAN]Life Sciences [q-bio]/CancerDiseaseGANCICLOVIRPlacebo01 natural sciencesPROPHYLAXIS03 medical and health sciencesDOUBLE-BLIND0302 clinical medicineMedicine General & Internal[SDV.CAN] Life Sciences [q-bio]/CancerInternal medicineGeneral & Internal MedicinemedicineCYTOMEGALOVIRUS DISEASE030212 general & internal medicine0101 mathematicsAdverse effectlcsh:R5-920Science & Technologybusiness.industryIncidence (epidemiology)010102 general mathematicsGeneral MedicineOdds ratioConfidence interval3. Good healthbusinessComplicationlcsh:Medicine (General)Life Sciences & BiomedicineResearch PaperEClinicalMedicine
researchProduct